Leukemia, other, Phase I-II

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Volunteers
Health Professionals

What is the purpose of this trial?

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Nikolai Podoltsev

nikolai.podoltsev@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Nikolai Podoltsev, MD, PhD
Associate Professor of Internal Medicine (Hematology); Duffy Firm Chief for Education, Department of Internal Medicine; Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine; Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology

Sub-Investigators

Last Updated
01/06/2025
Study HIC
#2000032345